BofA raised the firm’s price target on Krystal Biotech (KRYS) to $318 from $288 and keeps a Buy rating on the shares. Beyond commentary on continued growth for Vyjuvek, the firm expects timelines for NK data will be tracked closely as it sees this as “the largest binary for shares this year,” the analyst tells investors in an earnings preview for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech outlines rare disease growth strategy update
- Krystal Biotech price target raised to $336 from $320 at Citi
- Krystal Biotech price target raised to $306 from $202 at TD Cowen
- Krystal Biotech price target raised to $288 from $272 at BofA
- Krystal Biotech price target raised to $320 from $309 at Citi